WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317150

CAS#: 136470-78-5

Description: Abacavir (ABC) is an antiretroviral medication used to prevent and treat HIV/AIDS. It is of the nucleoside analog reverse transcriptase inhibitor (NRTI) type. Viral strains that are resistant to zidovudine (AZT) or lamivudine (3TC) are generally, but not always, sensitive to abacavir. It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. It is available under the trade name Ziagen and in the combination formulations abacavir/lamivudine/zidovudine, abacavir/dolutegravir/lamivudine, abacavir/lamivudine.

Price and Availability


USD 190
USD 950

USD 350
USD 1750

USD 650

Abacavir, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 317150
Name: Abacavir
CAS#: 136470-78-5
Chemical Formula: C14H18N6O
Exact Mass: 286.15421
Molecular Weight: 286.34
Elemental Analysis: C, 58.73; H, 6.34; N, 29.35; O, 5.59

Synonym: ABC, Ziagen; Epzicom; Abacavir.

IUPAC/Chemical Name: [(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol


InChi Code: InChI=1S/C14H18N6O/c15-14-18-12(17-9-2-3-9)11-13(19-14)20(7-16-11)10-4-1-8(5-10)6-21/h1,4,7-10,21H,2-3,5-6H2,(H3,15,17,18,19)/t8-,10+/m1/s1

SMILES Code: NC1=NC2=C(N=CN2[C@@H]2C[C@H](CO)C=C2)C(NC2CC2)=N1

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Fantauzzi A, Floridia M, Falasca F, Spanedda P, Turriziani O, Vullo V, Mezzaroma I. Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization. New Microbiol. 2015 Oct 20;38(4). [Epub ahead of print] PubMed PMID: 26485011.

2: Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Lancet Infect Dis. 2015 Oct 5. pii: S1473-3099(15)00319-9. doi: 10.1016/S1473-3099(15)00319-9. [Epub ahead of print] PubMed PMID: 26481928.

3: Naisbitt DJ, Yang EL, Alhaidari M, Berry NG, Lawrenson AS, Farrell J, Martin P, Strebel K, Owen A, Pye M, French N, Clarke SE, O'Neill PM, Park BK. Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation. AIDS. 2015 Sep 13. [Epub ahead of print] PubMed PMID: 26372480.

4: Wilson B, Paladugu L, Priyadarshini SR, Jenita JJ. Development of albumin-based nanoparticles for the delivery of abacavir. Int J Biol Macromol. 2015 Sep 10;81:763-767. doi: 10.1016/j.ijbiomac.2015.09.015. [Epub ahead of print] PubMed PMID: 26365020.

5: Tebas P, Kumar P, Hicks C, Granier C, Wynne B, Min S, Pappa K. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 2015 Sep 9. [Epub ahead of print] PubMed PMID: 26355674.

6: Walmsley S, Baumgarten A, Berenguer J, Felizarta F, Florence E, Khuong-Josses MA, Kilby JM, Lutz T, Podzamczer D, Portilla J, Roth N, Wong D, Granier C, Wynne B, Pappa K. Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results from the SINGLE Randomized Clinical Trial. J Acquir Immune Defic Syndr. 2015 Aug 7. [Epub ahead of print] PubMed PMID: 26262777.

7: Gao S, Zhu S, Huang R, Lu Y, Zheng G. Efficient synthesis of the intermediate of abacavir and carbovir using a novel (+)-γ-lactamase as a catalyst. Bioorg Med Chem Lett. 2015 Sep 15;25(18):3878-81. doi: 10.1016/j.bmcl.2015.07.054. Epub 2015 Jul 26. PubMed PMID: 26235952.

8: Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross LL, Shaefer MS. The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. HIV Med. 2015 Jul 14. doi: 10.1111/hiv.12281. [Epub ahead of print] PubMed PMID: 26176344.

9: Neumanova Z, Cerveny L, Greenwood SL, Ceckova M, Staud F. Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir. Reprod Toxicol. 2015 Nov;57:176-82. doi: 10.1016/j.reprotox.2015.07.070. Epub 2015 Jul 10. PubMed PMID: 26169552.

10: Young B, Squires KE, Tashima K, Henry K, Schneider S, LaMarca A, Zhao HH, Ross LL, Shaefer MS. Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2015 Aug;16(4):125-9. doi: 10.1179/1528433614Z.0000000017. Epub 2015 Jul 2. PubMed PMID: 26133089.